Dr. Myrna Francis Joins Covalon’s Board of Directors

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that Dr. Myrna Francis has joined Covalon’s Board of Directors.

Dr. Francis has an extensive background in healthcare and is well-known in both private and public sectors; her experience spans the international marketplace – Canada, the US, and Europe. She is currently the President of Mfran Healthcare Advisory Services. She is the Vice Chair of OCAD University’s Board of Governors and serves as a Board Director at Medavie Inc. and as a volunteer advisor for BioMedical Zone and MaRS Discovery District, Health Ventures Group. Dr. Francis has previously held positions as the CEO of Canada Health Infoway, Vice President, Global Healthcare Sector, at CGI Group Inc., Partner at CSC Healthcare Group, and numerous executive positions with the Ontario Ministry of Health. She has also served as a Board Director for a variety of companies and organizations, including RxCanada, Allstate Insurance Company of Canada, and Cedara Software Corp. She currently provides strategic advisory services in the public sector and to multinational private sector companies regarding health information technology, business transformation, business and product growth strategies, and innovation as an independent consultant. Dr. Francis holds a Master’s Degree in Psychology and Ph.D. in Medical Sciences, both from McMaster University, and a Multi-Party Negotiations Certification from Harvard Law School.

“I am looking forward to serving on Covalon’s Board of Directors,” said Dr. Francis. “I am familiar with Covalon’s management from my time as a Director at Cedara Software and have watched Covalon grow over the last few years. I am excited to participate in the guidance of this successful and growing company.”

“Covalon is delighted to have someone of Dr. Francis’ experience join our Board of Directors,” said Brian Pedlar, Chief Executive Officer. “Dr. Francis has significant experience in the healthcare industry and with both public and private boards, developed during her impressive career. The Covalon management team and board are looking forward to benefiting from Dr. Francis’ contribution as an independent board member.”

Dr. Francis’ appointment to Covalon’s Board of Directors is subject to TSX approval.

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon’s technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”, “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company’s ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005075/en/